Zobrazeno 1 - 10
of 97
pro vyhledávání: '"V Servent"'
Autor:
Lionel Uwer, Mony Ung, Etienne Brain, C. Lefeuvre-Plesse, Veronique Lorgis, Johann Le Fel, Morgane Abiven, Pierre Soubeyran, Marianne Leheurteur, Carine Bellera, Sophie Abadie-Lacourtoisie, Thomas Bachelot, Loïc Campion, Marie-Ange Mouret-Reynier, Olivier Villacroux, Anthony Gonçalves, Suzette Delaloge, Laurence Cristol-Dalstein, Eric Francois, Christelle Jouannaud, Thierry Petit, C. Courtinard, V. Servent, Mylène Annonay
Publikováno v:
Cancer Research. 80:P1-19
Background: Prognosis of women with HER2+ metastatic breast cancer (MBC) has radically improved over the past 10 years, resulting from the implementation in clinical of anti-HER2 therapies. However, there are limited data regarding these trends in th
Autor:
Carine Bellera, Christophe Perrin, Sophie Abadie-Lacourtoisie, Lisa Gauquelin, Marianne Leheurteur, Eric Francois, Catherine Terret, V. Servent, Romain Geiss, Veronique Lorgis, Christelle Jouannaud, Lionel Uwer, Suzette Delaloge, Anthony Gonçalves, Mony Ung, Etienne Brain, Thierry Petit, Olivier Villacroux, Florence Joly, Mylène Annonay, Coralie Courtinard, Pierre Soubeyran, Laurence Cristol-Dalstein, Johan Le Fel, Loïc Campion, Marie-Ange Mouret-Reynier
Publikováno v:
Breast
Breast, Elsevier, 2021, 60, pp.138-146. ⟨10.1016/j.breast.2021.09.011⟩
Breast, Vol 60, Iss, Pp 138-146 (2021)
The Breast : Official Journal of the European Society of Mastology
Breast, 2021, 60, pp.138-146. ⟨10.1016/j.breast.2021.09.011⟩
Breast, Elsevier, 2021, 60, pp.138-146. ⟨10.1016/j.breast.2021.09.011⟩
Breast, Vol 60, Iss, Pp 138-146 (2021)
The Breast : Official Journal of the European Society of Mastology
Breast, 2021, 60, pp.138-146. ⟨10.1016/j.breast.2021.09.011⟩
Background Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age. Methods Women who initiat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e3731ff80e1c38ffc118a60fc7423c5
https://hal.archives-ouvertes.fr/hal-03468488/file/BPH_TB_2021_Annonay.pdf
https://hal.archives-ouvertes.fr/hal-03468488/file/BPH_TB_2021_Annonay.pdf
Autor:
Aline Maillard, Brigitte Maget, Alban Rieger, Sophie C. Regueme, Rodolphe Thiébaut, Sandrine Lavau-Denes, Jessica Durrieu, Christophe Laurent, Eric Terrebonne, Haritz Arrieta, V. Servent, Cyril Astrugue, Marianne Fonck, Jérôme Dauba, Isabelle Bourdel-Marchasson
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 2, Pp 287-297 (2019)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, Wiley Open Access/Springer Verlag, 2019, 10 (2), pp.287-297. ⟨10.1002/jcsm.12382⟩
Addi. Archivo Digital para la Docencia y la Investigación
instname
Journal of Cachexia, Sarcopenia and Muscle, 2019, 10 (2), pp.287-297. ⟨10.1002/jcsm.12382⟩
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, Wiley Open Access/Springer Verlag, 2019, 10 (2), pp.287-297. ⟨10.1002/jcsm.12382⟩
Addi. Archivo Digital para la Docencia y la Investigación
instname
Journal of Cachexia, Sarcopenia and Muscle, 2019, 10 (2), pp.287-297. ⟨10.1002/jcsm.12382⟩
BACKGROUND: Older adults with cancer experience negative long-term functional effects of both cancer and treatments. Exercise may minimize their age-related and cancer-related functional decline. METHODS: We conducted a multicentre open-label 12month
Autor:
Jean-Yves Pierga, V. Servent, Véronique D'Hondt, Hugues Bourgeois, Véronique Diéras, William Jacot, Laurence Venat-Bouvet, Marie-Paule Sablin, Elisabeth Luporsi, Séverine Guiu, François-Clément Bidard, Frédérique Berger, Etienne Brain, Marc A. Bollet, Marc Espié, Alain Lortholary, Souhir Neffati, Coraline Dubot, Paul Cottu
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
BackgroundIn this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.MethodsMain inclusion criteria for screening were as follows: women
Publikováno v:
Cancer Research. 77:P5-14
Background: adjuvant or neoadjuvant chemotherapy in elderly patients (pts) is currently considered as a toxic treatment and reserved for fit women and high-risk breast cancer; few guidelines are available in this age group. The aim of this study was
Autor:
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, K Yakendji
Publikováno v:
Lancet (London, England). 393(10191)
Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned fin
Autor:
N. Chalabi, K.E. Benmammar, V. Servent, Sharif Kullab, Xavier Durando, I. van Praagh, Anne Cayre, Fabrice Kwiatkowski, Y-J Bignon, Nina Radosevic-Robin, M.M. Dauplat, Catherine Abrial, J.P. Jacquin, J-M Nabholtz, Frédérique Penault-Llorca, Ph. Chollet, Marie-Ange Mouret-Reynier, M.R.K. Bahadoor
Publikováno v:
International Journal of Cancer. 138:2274-2280
Systemic therapy for triple negative breast cancer (TNBC) is mostly based upon chemotherapy. Epithelial Growth Factor Receptor (EGFR) is overexpressed in around 50% of TNBC and may play a role in its pathogenesis. Consequently, we performed a multice
Autor:
E. Paillaud, P. Soubeyran, P. Caillet, T. Cudennec, E. Brain, C. Terret, F. Etchepare, L. Mourey, T. Aparicio, F. Pamoukdjian, R.A. Audisio, S. Rostoft, A. Hurria, C. Bellera, S. Mathoulin-Pélissier, R. Boulahssass, L. De Decker, V. Fossey-Diaz, E. Liuu, C. Mertens, L. Balardy, F. Retornaz, A.L. Couderc, F. Rollot-Trad, D. Azria, G. Bacciarello, E. Barranger, L. Bengrine, L. Bernat-Piazza, J.Y. Blay, E. Bourdolle, E. Carola, O. Chinot, J.M. Classe, R. Corre, S. Culine, H. Cure, S. Delaloge S, J.Y. Delattre, G. Desolneux, G. Freyer, P. Graff, J. Guigay, C. Herlin, K. Hoang-Xuan, A. Italiano, J.E. Kurtz, E. Lartigau, C. Lazarovicci-Nagera, I. Lebas, H. Le Caer, C. Maguire, O. Mir, S. Natur, C. Ortholan, A. Pigneux, M. Prou, R. Qabbal, F. Rousseau, R. Rouzier, A. Roveri, P. Sargos, S. Servagi, V. Servent, L. Ysebaert, S. Alibhai, L. Balducci, E. Bastiaannet, D. Bron, K. Cheng, H.J. Cohen, F. Cornelis, N. De Glas, T. Kalsi, R. Kanesvaran, C. Kenis, M. Hamaker, H. Holmes, T. Hsu, S. Lichtman, S. Mohile, A. O'Donovan, M. Puts, L. Repetto, N. Singhal, C. Steer, P. Stolz Baskett, W. Van De Water, B. Van Leuven, U. Wedding, T. Wildes, H. Wildiers, G. Zulian
Publikováno v:
European journal of cancer
European journal of cancer, 2018, 103, pp.61-68. ⟨10.1016/j.ejca.2018.07.137⟩
European journal of cancer, 2018, 103, pp.61-68. ⟨10.1016/j.ejca.2018.07.137⟩
Background To define a core set of geriatric data to be methodically collected in clinical cancer trials of older adults, enabling comparison across trials. Patients and methods Following a consensus approach, a panel of 14 geriatricians from oncolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1e309992a8be0c54852857c844e8928
https://hal.archives-ouvertes.fr/hal-03194137
https://hal.archives-ouvertes.fr/hal-03194137
Autor:
Jean-Louis Merlin, Frédéric Pinguet, Fabienne Thomas, N. Dohollou, Alexandre Evrard, Philippe Follana, Mireille Mousseau, Emmanuel Chamorey, Christophe Ferrand, Gérard Milano, Marie-Christine Etienne-Grimaldi, Gilles Romieu, André B.P. van Kuilenburg, Laurence Llorca, Rémy Largillier, V. Servent, Thomas Bachelot, Judith L Meijer, Litaty Mbatchi, David Salgado, Jean-Christophe Boyer, Jean-Pierre Desvignes, Véronique Diéras, Jacques Bonneterre, Yann Château, Christine Bobin-Dubigeon, Christophe Béroud, Etienne Chatelut, Henri Roché, Anthony Gonçalves, Loic Chaigneau, Jean-Marc Ferrero, Xavier Pivot
Publikováno v:
PLoS ONE
PLoS ONE, Public Library of Science, 2017, 12 (5), pp.e0175998. ⟨10.1371/journal.pone.0175998⟩
PLoS ONE, Public Library of Science, 2017, 12 (5), pp.e0175998. 〈10.1371/journal.pone.0175998〉
PLoS ONE, 2017, 12 (5), pp.e0175998. ⟨10.1371/journal.pone.0175998⟩
PLoS ONE, Vol 12, Iss 5, p e0175998 (2017)
PLoS ONE, 12(5). Public Library of Science
PLoS ONE, Public Library of Science, 2017, 12 (5), pp.e0175998. ⟨10.1371/journal.pone.0175998⟩
PLoS ONE, Public Library of Science, 2017, 12 (5), pp.e0175998. 〈10.1371/journal.pone.0175998〉
PLoS ONE, 2017, 12 (5), pp.e0175998. ⟨10.1371/journal.pone.0175998⟩
PLoS ONE, Vol 12, Iss 5, p e0175998 (2017)
PLoS ONE, 12(5). Public Library of Science
International audience; Background: Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b4684337b9f9ca84d09883437f02322
https://hal.archives-ouvertes.fr/hal-01780001/file/journal.pone.0175998.pdf
https://hal.archives-ouvertes.fr/hal-01780001/file/journal.pone.0175998.pdf